iSpecimen Inc. (ISPC) Debt Components
- 2024-10-31: Notes Payable, CurrentUSD (m); Long-term Debt, Current MaturitiesUSD $1.00M; Line of Credit Facility, Maximum Borrowing CapacityUSD (m); Debt Instrument, Face AmountUSD (m).
- 2024-09-30: Notes Payable, CurrentUSD $864.42K; Long-term Debt, Current MaturitiesUSD (m); Line of Credit Facility, Maximum Borrowing CapacityUSD (m); Debt Instrument, Face AmountUSD (m).
- 2024-09-19: Notes Payable, CurrentUSD (m); Long-term Debt, Current MaturitiesUSD (m); Line of Credit Facility, Maximum Borrowing CapacityUSD $1.00M; Debt Instrument, Face AmountUSD $1.00M.
- 2022-09-30: Notes Payable, CurrentUSD $816.67K; Long-term Debt, Current MaturitiesUSD (m); Line of Credit Facility, Maximum Borrowing CapacityUSD (m); Debt Instrument, Face AmountUSD (m).
iSpecimen Inc. Debt Components
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Notes Payable, Current USD | Long-term Debt, Current Maturities USD | Line of Credit Facility, Maximum Borrowing Capacity USD | Debt Instrument, Face Amount USD | Unsecured Debt, Current USD | Convertible Notes Payable, Current USD | Notes Payable USD | Long-term Debt USD | Long-Term Debt, Maturity, Year One USD | Long-Term Debt, Maturity, Year Two USD | Long-Term Debt, Maturity, Year Three USD | Long-Term Debt, Maturity, Year Four USD | Long-term Debt, Gross USD | Debt Instrument, Convertible, Conversion Price USD/shares |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2024-10-31 | (m) | $1.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $864.42K | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-19 | (m) | (m) | $1.00M | $1.00M | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $816.67K | (m) | (m) | (m) | (m) | (m) | (m) | $3.43M | $1.17M | $1.40M | $933.33K | (m) | $3.50M | (m) |
| 2022-06-30 | $466.67K | (m) | (m) | (m) | (m) | (m) | (m) | $3.43M | $1.17M | $1.40M | $933.33K | (m) | $3.50M | (m) |
| 2022-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $3.43M | $1.17M | $1.40M | $933.33K | (m) | $3.50M | (m) |
| 2021-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 5.60 |
| 2021-12-31 | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | $3.42M | (m) | $1.17M | $1.40M | $933.33K | $3.50M | (m) |
| 2021-09-30 | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 5.60 |
| 2021-06-30 | (m) | (m) | (m) | (m) | (m) | $0.00 | (m) | $3.00M | (m) | (m) | (m) | (m) | (m) | 5.60 |
| 2021-06-21 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | 5.60 |
| 2020-12-31 | $604.11K | (m) | (m) | (m) | $4.59M | (m) | $178.90K | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| FOXO TECHNOLOGIES INC. (FOXO) | United States | $0.000B | -277.71 |
| OneMedNet Corp (ONMD) | $0.042B | ||
| bioAffinity Technologies, Inc. (BIAF) | United States | $0.063B | |
| MAXCYTE, INC. (MXCT) | United States | $0.124B | -3.68 |
| NRC HEALTH (NRC) | United States | $0.450B | 42.50 |
| OmniAb, Inc. (OABI) | United States | $0.698B | -8.05 |
| Absci Corp (ABSI) | United States | $1.775B | -14.92 |
| CHARLES RIVER LABORATORIES INTERNATIONAL, INC. (CRL) | United States | $14.060B | -43.97 |
| Medpace Holdings, Inc. (MEDP) | United States | $17.316B | 30.09 |
| INCYTE CORP (INCY) | United States | $24.855B | 13.14 |